Current Approach to the Evaluation and Management of Microscopic Colitis
- 900 Downloads
Purpose of Review
Microscopic colitis is a common cause of chronic watery diarrhea, particularly in the elderly. The accompanying symptoms, which include abdominal pain and fatigue, can markedly impair patients’ quality of life. Diagnosis is based upon characteristic histologic findings of the colonic mucosa. This review focuses on the current approach to evaluation and management of patients with microscopic colitis.
Although the incidence of microscopic colitis has been increasing over time, recent epidemiological studies show stabilization at 21.0–24.7 cases per 100,000 person-years. Recent research has further expanded our knowledge of the underlying pathophysiology and emphasized the entity of drug-induced microscopic colitis and the association with celiac disease. Two recent randomized studies have confirmed the effectiveness of oral budesonide for both induction and maintenance treatment of microscopic colitis and is now endorsed by the American Gastroenterological Association as first-line treatment.
The incidence of microscopic colitis has stabilized at just over 20 cases per 100,000 person-years. Celiac disease and drug-induced microscopic colitis should be considered in all patients diagnosed with microscopic colitis. There are a number of treatments available for patients with microscopic colitis; however, budesonide is the only option well studied in controlled trials and is effective for both induction and maintenance treatment.
KeywordsMicroscopic colitis Microscopic colitis treatment Microscopic colitis management Large intestine
Compliance with Ethical Standards
Conflict of Interest
Thomas Cotter declares no conflict of interest. Darrell Pardi has served as a consultant to Salix, who markets Uceris.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •Of importance, ••Of major importance
- 9.Jarnerot G, Tysk C, Bohr J, et al. Collagenous colitis and fecal stream diversion. Gastroenterology. 1995;109:449–55.Google Scholar
- 10.• Verhaegh BP, de Vries F, Masclee AA, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 2016;43(9):1004–13. This large case-control study showed that current use of NSAIDs, PPIs and SSRIs was all significantly associated with microscopic colitis, with a fivefold increased risk noted with concomitant PPI and NSAID use, emphasizing the importance of recognizing the entity of drug-induced microscopic colitis. This analysis also provided further insight into the potential pathophysiology of drug-induced microscopic colitis, including the hypothesis of PPI-induced intestinal dysbiosis related to acid suppression. Google Scholar
- 11.Roda G TJ, Hu J, et al. Genome-wide association identifies multiple collagenous colitis susceptibility loci. Gastroenterology. 2015;148(4) Suppl 1:S–875.Google Scholar
- 17.Guagnozzi D, Arias A, Lucendo AJ. Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders. Aliment Pharmacol Ther. 2016. doi: 10.1111/apt.13573.
- 19.Cotter TG, Binder M, Harper EP, et al. Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. J Clin Gastroenterol. 2016. doi: 10.1097/MCG.0000000000000565.
- 28.•• Cotter TG, Binder M, Loftus EV, Jr., et al. Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut. 2016. doi: 10.1136/gutjnl-2016-313051. This prospective cohort study developed the Microscopic Colitis Disease Activity Index (MCDAI) consisting of six patient-reported variables: unformed stools daily, nocturnal stools, abdominal pain, weight loss, faecal urgency and faecal incontinence. It is hoped that the MCDAI can be used to consistently score disease severity in clinical trials, enabling meaningful comparisons between different treatments in the future.
- 32.Gentile NM KS, Loftus EV, et al. Outcomes of patients with microscopic colitis treated with bismuth subsalicylate. Gastroenterology 2015;148:S-483.Google Scholar
- 35.•• Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 2014;146:1222-30 e1-2. This randomized placebo-controlled control trial showed oral budesonide (9 mg once daily) to be effective and safe for short-term treatment of collagenous colitis. Short-term treatment with oral mesalamine appeared to be ineffective. Google Scholar
- 52.••Munch A, Bohr J, Miehlke S, et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut. 2016;65:47–56. This randomized placebo-controlled trial revealed budesonide, at a mean dose of 4.5 mg/day, to be effective in maintaining clinical remission for 1 year in patients with collagenous colitis without safety concerns. This trial also suggested that treatment extension beyond 1 year may be beneficial, given the high relapse rate after budesonide discontinuation. CrossRefPubMedGoogle Scholar
- 59.Anderson RJ, Makins R. Successful use of adalimumab in patient with treatment-refractory microscopic colitis. BMJ Case Rep. 2016. doi: 10.1136/bcr-2016-215639.